Skip to main content

Advertisement

SpringerLink
Log in

Advances in bio-immunotherapy for castration-resistant prostate cancer

  • Review
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Prostate cancer is one of the significant diseases that threaten the survival of men worldwide, with the progression of androgen deprivation therapy, become much rely on it, finally, developed into castration-resistant prostate cancer (ADT). In western countries, ranks second in incidence, and in China, with increasing lifespan, the incidence of prostate cancer is rising steadily. Although chemotherapy agents, such as taxane, have achieved some efficacy, treatment failure still occur. As sensitivity of hormone levels change, the disease can progress to castrate-resistant prostate cancer. Because of the poor efficacy of traditional surgery, endocrine therapy, radiation therapy, and chemotherapy, the treatment options for castrate-resistant prostate cancer are limited. Advanced prostate cancer can progress on immunotherapy, and thus, bio -immunotherapy targeting the unique, prostate microenvironment is an important option. In this paper, we systematically revealed the role of three types of bio-immunotherapies (immune checkpoint inhibitors, tumors, vaccines, cytokines) in castrate-resistant prostate cancer, providing a reference for clinical treatment of prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure1

Similar content being viewed by others

Data availability

In conclusion of all data availability generated or analyzed during this study are included in this published article.

References

  • Alabi BR, Liu S, Stoyanova T (2022) Current and emerging therapies for neuroendocrine prostate cancer. Pharmacol Ther 238:108255

    CAS  PubMed  Google Scholar 

  • Ardiani A, Farsaci B, Rogers CJ et al (2013) Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model. Clin Cancer Res 19(22):6205–6218

    CAS  PubMed  Google Scholar 

  • Baeuerle PA, Kufer P, Bargou R (2009) BiTE: teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 11(1):22–30

    CAS  PubMed  Google Scholar 

  • Barqawi AB, Rodrigues Pessoa R, Crawford ED et al (2021) Boosting immune response with GM-CSF optimizes primary cryotherapy outcomes in the treatment of prostate cancer: a prospective randomized clinical trial. Prostate Cancer Prostatic Dis 24(3):750–757

    CAS  PubMed  Google Scholar 

  • Bonnefoy N, Olive D, Vanhove B (2019) Next generation of anti-immune checkpoints antibodies. Med Sci (paris) 35(12):966–974

    PubMed  Google Scholar 

  • Brunet JF, Denizot F, Luciani MF et al (1987) A new member of the immunoglobulin superfamily–CTLA-4. Nature 328(6127):267–270

    CAS  PubMed  Google Scholar 

  • Carosella ED, Ploussard G, Lemaoult J et al (2015) A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/PD- L1, and HLA-G. Eur Urol 68(2):267–279

    CAS  PubMed  Google Scholar 

  • Chen J, Zhang H, Zhou L et al (2020) Enhancing the efficacy of tumor vaccines based on immune evasion mechanisms. Front Oncol 10:584367

    PubMed  Google Scholar 

  • Czernin J, Current K, Mona CE et al (2021) Immune-checkpoint blockade enhances (225)Ac-PSMA617 efficacy in a mouse model of prostate cancer. J Nucl Med 62(2):228–231

    CAS  PubMed  Google Scholar 

  • Deng X, Xiong F, Li X et al (2018) Application of atomic force microscopy in cancer research. J Nanobiotechnol 16(1):102

    CAS  Google Scholar 

  • Deng S, Zhou X, Xu J (2020) Checkpoints under traffic control: from and to organelles. Adv Exp Med Biol 1248:431–453

    CAS  PubMed  Google Scholar 

  • Dholakia J, Cohen AC, Leath CA 3rd et al (2022) Development of delivery systems for local administration of cytokines/cytokine gene-directed therapeutics: modern implications. Curr Oncol Rep 24(4):389–397

    CAS  PubMed  PubMed Central  Google Scholar 

  • Dranoff G, Jaffee E, Lazenby A et al (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90(8):3539–3543

    CAS  PubMed  PubMed Central  Google Scholar 

  • Fizazi K, Drake CG, Beer TM et al (2020) Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors. Eur Urol 78(6):822–830

    CAS  PubMed  PubMed Central  Google Scholar 

  • Graff JN, Liang LW, Kim J et al (2021) KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer. Future Oncol 17(23):3017–3026

    CAS  PubMed  Google Scholar 

  • Grenier JM, Yeung ST, Khanna KM (2018) Combination immunotherapy: taking cancer vaccines to the next level. Front Immunol 9:610

    PubMed  PubMed Central  Google Scholar 

  • Gulley JL, Borre M, Vogelzang NJ et al (2019) Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. J Clin Oncol 37(13):1051–1061

    CAS  PubMed  PubMed Central  Google Scholar 

  • Hafron JM, Wilfehrt HM, Ferro C et al (2022) Real-world effectiveness of sipuleucel-T on overall survival in men with advanced prostate cancer treated with androgen receptor-targeting agents. Adv Ther 39(6):2515–2532

    PubMed  PubMed Central  Google Scholar 

  • Hansen AR, Massard C, Ott PA et al (2018) Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol 29(8):1807–1813

    CAS  PubMed  Google Scholar 

  • Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723

    CAS  PubMed  PubMed Central  Google Scholar 

  • Isaacsson Velho P, Antonarakis ES (2018) PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol 11(5):475–486

    CAS  PubMed  Google Scholar 

  • Jiang X, Wang J, Deng X et al (2019) Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer 18(1):10

    PubMed  PubMed Central  Google Scholar 

  • Johnson LE, Frye TP, Arnot AR et al (2006) Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine 24(3):293–303

    CAS  PubMed  Google Scholar 

  • Junghans RP, Ma QZ, Rathore R et al (2016) Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response. Prostate 76(14):1257–1270

    CAS  PubMed  Google Scholar 

  • Kole C, Charalampakis N, Tsakatikas S et al (2020) Immunotherapy for hepatocellular carcinoma: a 2021 update. Cancers (basel) 12(10):2859

    CAS  PubMed  Google Scholar 

  • Lamont KR, Tindall DJ (2010) Androgen regulation of gene expression. Adv Cancer Res 107:137–162

    CAS  PubMed  Google Scholar 

  • Lasek W, Zapała Ł (2021) Therapeutic metastatic prostate cancer vaccines: lessons learnt from urologic oncology. Cent European J Urol 74(3):300–307

    CAS  PubMed  PubMed Central  Google Scholar 

  • Lazarus HM, Ragsdale CE, Gale RP et al (2021) Sargramostim (rhu GM-CSF) as cancer therapy (systematic review) and an immunomodulator. A drug before its time? Front Immunol 12:706186

    CAS  PubMed  PubMed Central  Google Scholar 

  • Lin H, Liu Q, Zeng X et al (2021) Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study. BMC Cancer 21(1):399

    CAS  PubMed  PubMed Central  Google Scholar 

  • Madan RA, Karzai F, Donahue RN et al (2021) Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer. J Immunother Cancer 9(3):e001556

    PubMed  PubMed Central  Google Scholar 

  • McNeel DG, Eickhoff JC, Johnson LE et al (2019) Phase II trial of a dna vaccine encoding prostatic acid phosphatase (pTVG-HP [MVI-816]) in patients with progressive, nonmetastatic, castration-sensitive prostate cancer. J Clin Oncol 37(36):3507–3517

    CAS  PubMed  PubMed Central  Google Scholar 

  • Michael BD, Syndikus I, Clark A et al (2010) Diffuse primary leptomeningeal melanocytosis in a patient receiving a novel cancer cell vaccine for prostate cancer. BMJ Case Rep 2010:bcr1120092495

    Google Scholar 

  • Noguchi M, Fujimoto K, Arai G et al (2021) A randomized phase III trial of personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel. Oncol Rep 45(1):159–168

    PubMed  Google Scholar 

  • Olson BM, Johnson LE, McNeel DG (2013) The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Cancer Immunol Immunother 62(3):585–596

    CAS  PubMed  Google Scholar 

  • Olson BM, Bradley ES, Sawicki T et al (2017) Safety and immunological efficacy of a DNA vaccine encoding the androgen receptor ligand-binding domain (AR-LBD). Prostate 77(7):812–821

    CAS  PubMed  PubMed Central  Google Scholar 

  • Pachynski RK, Morishima C, Szmulewitz R et al (2021) IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC). J Immunother Cancer 9(8):e002903

    PubMed  PubMed Central  Google Scholar 

  • Park JH, Rivière I, Gonen M et al (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378(5):449–459

    CAS  PubMed  PubMed Central  Google Scholar 

  • Paweletz KL, Li S, Bailis JM et al (2020) Combination of AMG 160, a PSMA x CD3 half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, with an anti-PD-1 antibody in prostate cancer (PCa). J Clin Oncol 38(6):155

    Google Scholar 

  • Potluri HK, Ng TL, Newton MA et al (2022) GM-CSF elicits antibodies to tumor-associated proteins when used as a prostate cancer vaccine adjuvant. Cancer Immunol Immunother 71(9):2267–2275

    CAS  PubMed  PubMed Central  Google Scholar 

  • Reimers MA, Slane KE, Pachynski RK (2019) Immunotherapy in metastatic castration-resistant prostate cancer: past and future strategies for optimization. Curr Urol Rep 20(10):64

    PubMed  Google Scholar 

  • Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359(6382):1350–1355

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ross AE, Hurley PJ, Tran PT et al (2020) A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate. Prostate Cancer Prostatic Dis 23(1):184–193

    CAS  PubMed  Google Scholar 

  • Sanda MG, Smith DC, Charles LG et al (1999) Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 53(2):260–266

    CAS  PubMed  Google Scholar 

  • Sasada T, Noguchi M, Yamada A et al (2012) Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer. Hum Vaccin Immunother 8(9):1309–1313

    CAS  PubMed  PubMed Central  Google Scholar 

  • Schellhammer PF, Chodak G, Whitmore JB et al (2013) Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial. Urology 81(6):1297–1302

    PubMed  Google Scholar 

  • Schepisi G, Cursano MC, Casadei C et al (2019) CAR-T cell therapy: a potential new strategy against prostate cancer. J Immunother Cancer. https://doi.org/10.1186/s40425-019-0741-7

    Article  PubMed  PubMed Central  Google Scholar 

  • Schilling G, Arnold D (2020) Basic principles of immunotherapy. Radiologe 60(8):682–686

    PubMed  Google Scholar 

  • Schuster SJ, Bishop MR, Tam CS et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45–56

    CAS  PubMed  Google Scholar 

  • Sharma P, Sohn J, Shin SJ et al (2020) Efficacy and tolerability of tremelimumab in locally advanced or metastatic urothelial carcinoma patients who have failed first- line platinum-based chemotherapy. Clin Cancer Res 26(1):61–70

    CAS  PubMed  Google Scholar 

  • Shimabukuro-Vornhagen A, Gödel P, Subklewe M et al (2018) Cytokine release syndrome. J Immunother Cancer 6(1):56

    PubMed  PubMed Central  Google Scholar 

  • 孙帅, 朱颐申, 韦萍 (2017) PROSTVAC~□——一种前列腺癌治疗性疫苗的研究进展. 中国疫苗和免疫, 23(01):105–109

  • Small EJ, Sacks N, Nemunaitis J et al (2007) Granulocyte macrophage colony-stimulating factor–secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 13(13):3883–3891

    CAS  PubMed  Google Scholar 

  • Subudhi SK, Siddiqui BA, Aparicio AM et al (2021) Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. J Immunother Cancer 9(10):e002919

    PubMed  PubMed Central  Google Scholar 

  • Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249

    PubMed  Google Scholar 

  • Tarrar TA, Anwar MY, Ali MA et al (2022) Current status of monoclonal antibodies-based therapies in castration-resistant prostate cancer: a systematic review and meta-analysis of clinical trials. Cureus 14(3):e22942

    PubMed  PubMed Central  Google Scholar 

  • Teo MY, Rathkopf DE, Kantoff P (2019) Treatment of advanced prostate cancer. Annu Rev Med 70:479–499

    CAS  PubMed  PubMed Central  Google Scholar 

  • Thomas S, Prendergast GC (2016) Cancer vaccines: a brief overview. Methods Mol Biol 1403:755–761

    PubMed  Google Scholar 

  • van Coillie S, Wiernicki B, Xu J (2020) Molecular and cellular functions of CTLA-4. Adv Exp Med Biol 1248:7–32

    PubMed  Google Scholar 

  • Vuky J, Corman JM, Porter C et al (2013) Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer. Oncologist 18(6):687–688

    PubMed  PubMed Central  Google Scholar 

  • Yerramilli D, Walsh E, Turner E et al (2018) Cancer-related morbidity at the end of life in men with prostate cancer. J Clin Oncol 36(15_suppl):5042

    Google Scholar 

  • Yu EY, Piulats Rodriguez JMM, Gravis G et al (2020) Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results. American Society of Clinical Oncology

  • Zuccolotto G, Fracasso G, Merlo A et al (2014) PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models. PLoS ONE 9(10):e109427

    PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported by the Natural Science Foundation of Jiangxi Province (no. 20202BABL206079), funder is WHY.

Author information

Authors and Affiliations

  1. Yichun University, Yichun, 336000, Jiangxi, China

    Canling Lin, Yonghui Chen & Liji Shi

  2. Department of Oncology, The People’s Hospital of Yichun Affiliated to Clinical Medicine School, Yichun, 336000, Jiangxi, China

    Hongmei Xia & Weihua Yin

  3. The Graduate School of Fujian Medical University, Fuzhou, 350122, Fujian, China

    Huarong Lin

Authors
  1. Canling Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yonghui Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Liji Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Huarong Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hongmei Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Weihua Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LCL conceived the ideas and directed the research; YWH revised the manuscript; CYH, LHR, SLJ, and XHM carried out the scientific literature search, data collection; all authors read and approved the manuscript.

Corresponding author

Correspondence to Weihua Yin.

Ethics declarations

Conflict of interest

The authors all declared no conflicts of interest.

Ethics statement

Approval of the research protocol by an Institutional Reviewer Board: N/A. Informed Consent: N/A. Registry and the Registration No. of the study/trial: N/A. Animal Studies: N/A.

Consent for publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lin, C., Chen, Y., Shi, L. et al. Advances in bio-immunotherapy for castration-resistant prostate cancer. J Cancer Res Clin Oncol 149, 13451–13458 (2023). https://doi.org/10.1007/s00432-023-05152-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-023-05152-9

Keywords

Search

Navigation